SUFFOLK, U.K., July 17, 2003 (PRIMEZONE) -- Celsis Laboratory Group (Other OTC:CEITF), part of the Celsis International Plc group of companies, a leading US supplier of cGMP analytical services for the pharmaceutical industry, has entered into a master services agreement with Sanofi-Synthelabo. Celsis will provide various chemistry and microbiology analytical testing services to Sanofi-Synthelabo's US and Puerto Rican subsidiaries.
Sanofi-Synthelabo principle area of business is ethical pharmaceuticals and the company ranks among the world's top twenty pharmaceutical companies. Their core therapeutic areas are cardiovascular disease and thrombosis, diseases of the central nervous system, cancer and internal medicine.
Jay LeCoque, Chief Executive Officer, Celsis stated: "Establishing this agreement with Sanofi-Synthelabo, a major pharmaceutical company, is a great success for Celsis and highlights our Laboratory Group's new business development strategy is having an impact. We will continue to expand our customer base by providing high quality services with superior customer service to maintain our leading position in the cGMP testing arena."
Notes to editors Celsis Laboratory Group Celsis Laboratory Group, part of the Celsis International plc group of companies, is a leading US supplier of cGMP analytical services. Celsis Laboratory Group provides a cost effective and broad range of quality control testing services to its customers. Many Fortune 500 companies in the pharmaceutical, chemical and cosmetic industries have come to rely upon the Celsis Laboratory Group to fulfil their testing needs.
Celsis Laboratory Group's services include comprehensive testing in the areas of analytical chemistry, microbiology, stability storage & testing and quality assurance. With facilities in Edison, New Jersey, (USA) and St Louis, Missouri, (USA) Celsis Laboratory Group has a uniform commitment to quality and customer service across its operations. Both laboratories are FDA registered and function under current Good Manufacturing Practices (cGMP) and applicable Good Laboratory Practices (GLP) and have been successfully audited by regulatory agencies (FDA, EPA, DEA) and 9 out of the top 10 worldwide pharmaceutical companies.
For more information on Celsis International Plc or Celsis Laboratory Group go to www.celsis.com